Merck KGaA enters USD3B AI drug discovery partnership with Valo Health to target Parkinson’s disease

GERMANY— Merck KGaA has entered into a strategic partnership with Valo Health, joining a growing list of major pharmaceutical companies leveraging the tech firm’s artificial intelligence capabilities to discover breakthrough therapeutics.

Under the terms of the agreement, Merck will provide Valo with more than USD3 billion in potential upfront and milestone payments, alongside research and development funding and royalties from any successful products that emerge from the collaboration.

Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.

The collaboration specifically targets therapeutic discovery for Parkinson’s disease and related neurological disorders, addressing an area of significant unmet medical need.

Valo’s human causal biology platform harnesses artificial intelligence to analyze more than 17 million de-identified patient records and biobank samples, enabling researchers to pinpoint promising therapeutic targets with unprecedented precision.

In the field of neurological disorders, the company’s technology has successfully identified distinct patient phenotypes across the entire disease spectrum, providing valuable insights into the complexity of conditions like Parkinson’s disease.

Once potential targets are identified, Valo’s closed-loop chemistry platform takes over the next phase of discovery by developing small molecules designed to engage these disease targets effectively.

This integrated approach combines vast real-world data analysis with practical drug development capabilities, creating a comprehensive pathway from target identification to candidate molecules.

Amy Kao, who heads Merck’s global neurology and immunology research unit, emphasized the partnership’s strategic importance by explaining that the company’s research engine focuses on delivering meaningful medicines for patients facing high unmet medical needs.

She noted that Valo Health’s AI-enabled platforms, which utilize human data, will help sharpen target selection and streamline the drug discovery process, ultimately enabling the company to advance the most promising candidates more quickly.

While Valo maintains its own internal drug development pipeline, partnerships with major pharmaceutical companies have increasingly become a crucial commercial strategy for the organization.

This shift in focus gained momentum after the company’s diabetic retinopathy candidate, OPL-0401, failed to meet endpoints in a Phase II clinical trial.

Following this setback, Valo redirected its attention toward leveraging its extensive collection of real-world data.

The company has not publicly disclosed details about other assets currently in its development pipeline.

However, Valo has been transparent about the high-value partnerships it continues to secure with pharmaceutical giants seeking to enhance their pipelines with next-generation therapeutics.

Danish drugmaker Novo Nordisk maintains an ongoing collaboration with Valo worth up to USD 4.6 billion if the partnership achieves certain development milestones in cardiometabolic indications.

Additionally, Pfizer works with Valo through a ten-program agreement established with the company’s founder, Flagship Pioneering.

The trend of pharmaceutical companies partnering with AI-powered platform providers has accelerated significantly in recent years throughout the industry.

Research conducted by GlobalData indicates that artificial intelligence’s speed and efficiency can substantially reduce both drug development costs and timelines, making these partnerships increasingly attractive to traditional pharmaceutical companies looking to enhance their research and development capabilities.

Valo’s CEO Brian Alexander expressed enthusiasm about using the company’s platform to expand Merck’s portfolio of treatments for Parkinson’s disease and related disorders.

Alexander explained that starting with human causal biology embedded in vast amounts of real-world data allows researchers to unravel the complexity of heterogeneous diseases like Parkinson’s.

This approach enables teams to begin experimentation with human-validated mechanisms, providing greater confidence that a target will successfully translate into a viable therapeutic candidate.

 Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.